论文部分内容阅读
目的:探讨钙离子结合蛋白S100A9在乳腺癌患者中的表达及临床意义。方法:选取39例乳腺癌患者术前、15例术后血清及10例健康女性血清,12例手术切除肿瘤组织标本,应用ELISA检测乳腺癌患者血清S100A9水平,采用免疫组织化学方法检测乳腺癌组织中S100A9的表达,分析S100A9表达与临床病理特征的关系。结果:S100A9在乳腺癌组患者血清中表达水平高于健康组(P<0.01),有淋巴结转移乳腺癌组血清S100A9表达水平高于无淋巴结组(P<0.01),乳腺癌患者术后S100A9血清表达水平降低(P<0.01)。乳腺癌患者血清中S100A9水平与患者年龄、肿瘤最大径、组织学分级和病理类型有关(P<0.01)。S100A9在乳腺癌组织中表达明显高于癌旁正常组织。结论:S100A9表达水平在乳腺癌血清和组织中明显升高,表明S100A9可作为乳腺癌患者诊断和疗效观察指标。
Objective: To investigate the expression and clinical significance of calcium ion binding protein S100A9 in breast cancer patients. Methods: Thirty-nine breast cancer patients were selected before operation, 15 postoperative serums and 10 healthy female serums. Tissue samples of 12 patients were removed surgically. Serum levels of S100A9 in breast cancer patients were detected by ELISA. Immunohistochemistry was used to detect breast cancer tissues S100A9 expression, analysis of S100A9 expression and clinicopathological features. Results: The expression of S100A9 in breast cancer patients was significantly higher than that in healthy controls (P <0.01). The level of S100A9 in breast cancer patients with lymph node metastasis was higher than that in non-lymph node patients (P <0.01) The expression level decreased (P <0.01). Serum levels of S100A9 in breast cancer patients were related to patient age, tumor diameter, histological grade and pathological type (P <0.01). The expression of S100A9 in breast cancer tissues was significantly higher than that in adjacent normal tissues. Conclusion: S100A9 expression in breast cancer serum and tissue was significantly increased, indicating that S100A9 can be used as a marker of diagnosis and efficacy of breast cancer patients.